Meeting
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Authors
Alessandro Santin
Yale School of Medicine, New Haven, CT
Alessandro Santin , Bradley Corr , Alexander I. Spira , Lyndsay Willmott , James Edward Butrynski , Ka Yu Tse , Jilpa Patel , Sabeen Mekan , Tia Wu , Ecaterina Elena Dumbrava
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
NCT03964727
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5610)
DOI
10.1200/JCO.2023.41.16_suppl.5610
Abstract #
5610
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
First Author: Alessandro Santin
First Author: B.J. Rimel
Poster
2020 ASCO Virtual Scientific Program
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.
First Author: Ashish Saxena
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu